We are live on
!
Find out more
NTC
North Tide Capital Portfolio holdings
AUM
$469M
1-Year Est. Return
6.57%
This Fund
S&P 500
This Quarter
Est. Return
+12.26%
1 Year Est. Return
+6.57%
3 Year Est. Return
+14.81%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.49B
AUM Growth
+$175M
(+13%)
Cap. Flow
+$37.1M
Cap. Flow
% of AUM
2.5%
Top 10 Holdings %
Top 10 Hldgs %
67.93%
Holding
27
New
2
Increased
7
Reduced
2
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$55.7M |
| 2 |
KND
Kindred Healthcare
KND
|
+$34.6M |
| 3 |
Quest Diagnostics
DGX
|
+$31.6M |
| 4 |
SVU
SUPERVALU Inc.
SVU
|
+$31.2M |
| 5 |
MGLN
Magellan Health Services, Inc.
MGLN
|
+$11.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$76.6M |
| 2 |
AbbVie
ABBV
|
+$63M |
| 3 |
WW
WW International
WW
|
+$8.06M |
| 4 |
NUVA
NuVasive, Inc.
NUVA
|
+$4.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.37% |
| 2 | Consumer Discretionary | 4.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SEM
1
DELISTED
Select Medical
SEM
| $201M | 13.5% |
25,891,200
| – | – |
|
|
2
Teva Pharmaceuticals
TEVA
$37.3B
| $173M | 11.59% |
3,000,000
+1,000,000
| +50% | +$55.7M |
|
|
AMED
3
DELISTED
Amedisys
AMED
| $117M | 7.89% |
4,000,000
| – | – |
|
|
KND
4
DELISTED
Kindred Healthcare
KND
| $90.9M | 6.11% |
5,000,000
+1,750,000
| +54% | +$34.6M |
|
5
Viatris
VTRS
$20.1B
| $84.6M | 5.68% |
1,500,000
| – | – |
|
|
TVTY
6
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $76.5M | 5.14% |
3,850,000
| – | – |
|
7
Bausch Health
BHC
$1.8B
| $71.6M | 4.81% |
500,000
| – | – |
|
|
8
Quest Diagnostics
DGX
$23.3B
| $67.1M | 4.51% |
1,000,000
+500,000
| +100% | +$31.6M |
|
9
Boston Scientific
BSX
$65.4B
| $66.3M | 4.45% |
5,000,000
| – | – |
|
|
SVU
10
DELISTED
SUPERVALU Inc.
SVU
| $63M | 4.24% |
928,571
+500,000
| +117% | +$31.2M |
|
11
Orthofix Medical
OFIX
$468M
| $54.1M | 3.64% |
1,800,000
| – | – |
|
|
GHDX
12
DELISTED
Genomic Health, Inc.
GHDX
| $48M | 3.22% |
1,500,000
| – | – |
|
|
WW
13
DELISTED
WW International
WW
| $42.2M | 2.84% |
1,700,000
-300,000
| -15% | -$8.06M |
|
|
MGLN
14
DELISTED
Magellan Health Services, Inc.
MGLN
| $42M | 2.82% |
700,000
+200,000
| +40% | +$11.8M |
|
|
GTIV
15
DELISTED
GENTIVA HEALTH SERVICES INC
GTIV
| $38.1M | 2.56% |
2,000,000
| – | – |
|
16
Myriad Genetics
MYGN
$584M
| $37.5M | 2.52% |
1,100,000
+100,000
| +10% | +$3.55M |
|
|
17
AbbVie
ABBV
$450B
| $32.7M | 2.2% |
500,000
-1,000,000
| -67% | -$63M |
|
|
VVUS
18
DELISTED
Vivus Inc
VVUS
| $32.6M | 2.19% |
1,130,480
+130,480
| +13% | +$4.25M |
|
|
AFAM
19
DELISTED
Almost Family Inc
AFAM
| $31.6M | 2.12% |
1,090,500
| – | – |
|
|
MNTA
20
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $30.1M | 2.02% |
2,500,000
| – | – |
|
|
ELOS
21
DELISTED
Syneron Medical Ltd
ELOS
| $28M | 1.88% |
3,000,000
| – | – |
|
|
FRED
22
DELISTED
Fred's Inc
FRED
| $26.1M | 1.76% |
1,500,000
| – | – |
|
23
Accuray
ARAY
$30.8M
| $15.1M | 1.01% |
2,000,000
| – | – |
|
|
RAD
24
DELISTED
Rite Aid Corporation
RAD
| $15M | 1.01% |
+100,000
| New | +$11.1M |
|
|
AEGR
25
DELISTED
Aegerion Pharmaceuticals
AEGR
| $4.19M | 0.28% |
+200,000
| New | +$5.04M |
|
Similar funds
SD
DG
NBC
JWM
JPCCM
MCL
GIIO
FC
North Tide Capital's Q4 2014 Portfolio in Review
As of Q4 2014, North Tide Capital held 27 positions worth $1.49B, up 13% from $1.31B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
North Tide Capital's Q4 2014 filing shows 2 new, 7 increased, 2 reduced and 2 closed positions. Its largest new stake was Rite Aid Corporation: 100,000 shares worth $15M. The largest sale was Edwards Lifesciences, an estimated $76.6M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 82% a quarter earlier, followed by Consumer Discretionary.
- North Tide Capital's largest Q4 2014 buy was Rite Aid Corporation: 100,000 shares worth $15M.
- North Tide Capital added most to Teva Pharmaceuticals in Q4 2014, an estimated $55.7M increase.
- North Tide Capital's biggest Q4 2014 reduction was AbbVie, cutting an estimated $63M.
- North Tide Capital fully exited Edwards Lifesciences in Q4 2014, selling an estimated $76.6M.
- North Tide Capital's ten largest holdings make up 68% of its $1.49B portfolio in Q4 2014.
- North Tide Capital opened 2 new positions and closed 2 in Q4 2014.
- North Tide Capital's portfolio value rose 13% quarter-over-quarter to $1.49B.
Based on North Tide Capital's 13F filing for Q4 2014, filed 13 Feb 2015.